Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Reid Weyant Merryman, M.D.

Concepts (82)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Hodgkin Disease13202314153.760 Why?
Hematopoietic Stem Cell Transplantation17202354452.260 Why?
Lymphoma, Mantle-Cell320232331.520 Why?
Transplantation, Autologous12202321231.150 Why?
Lymphoma, Large B-Cell, Diffuse7202313771.020 Why?
Lymphoma, Non-Hodgkin3202013810.910 Why?
Neoplasm Recurrence, Local12202392390.810 Why?
Immunotherapy, Adoptive5202312710.750 Why?
Lymphoma, Follicular120234350.700 Why?
Neurotoxicity Syndromes120232900.690 Why?
Salvage Therapy4202112750.640 Why?
Immune Evasion120193600.550 Why?
Antineoplastic Combined Chemotherapy Protocols92023115240.460 Why?
Stem Cell Transplantation5202316200.440 Why?
Asparaginase120122360.380 Why?
Neoplasm, Residual320239730.350 Why?
Drug Resistance, Neoplasm2202151700.340 Why?
Lymphoma1201718750.310 Why?
Antineoplastic Agents32023136910.300 Why?
Leukocytes, Mononuclear2202318360.270 Why?
Transplantation Conditioning4202115990.260 Why?
Schools, Medical120118790.240 Why?
Transplantation, Homologous3202147770.230 Why?
Positron-Emission Tomography2202262370.220 Why?
Precursor Cell Lymphoblastic Leukemia-Lymphoma1201215200.220 Why?
Antibodies, Monoclonal5202392720.220 Why?
Lymphoma, T-Cell, Peripheral120231340.200 Why?
Antigens, CD19120233800.190 Why?
Disease-Free Survival6202368950.180 Why?
Education, Medical1201117220.170 Why?
Humans3020237438110.170 Why?
Health Policy1201126620.160 Why?
Retrospective Studies112022774100.160 Why?
Cytarabine120206920.160 Why?
Antibodies, Bispecific120201640.160 Why?
Combined Modality Therapy2202086370.140 Why?
Proto-Oncogene Proteins c-bcl-6120161930.140 Why?
Central Nervous System1202313580.130 Why?
Immunoconjugates120229010.120 Why?
Graft vs Host Disease2201729580.120 Why?
Receptors, Antigen, T-Cell1202325400.120 Why?
Survival Rate42022127860.120 Why?
Clinical Trials as Topic2202079080.120 Why?
Prognosis32022290520.110 Why?
Tumor Microenvironment1202335830.100 Why?
Proto-Oncogene Proteins c-myc120169880.100 Why?
Statistics, Nonparametric1201728830.100 Why?
Immunotherapy2202344370.090 Why?
Adult1020232138890.090 Why?
Proto-Oncogene Proteins c-bcl-21201614340.090 Why?
T-Lymphocytes22023101790.080 Why?
Young Adult32021563920.080 Why?
Molecular Targeted Therapy1202027270.080 Why?
CD8-Positive T-Lymphocytes1202144770.080 Why?
Neoplasms12017216750.080 Why?
Treatment Outcome32023630420.070 Why?
Kaplan-Meier Estimate1201765390.070 Why?
Neoplasm Proteins1201837060.070 Why?
Methotrexate1201217260.060 Why?
Hematologic Neoplasms1201718320.060 Why?
Aged820221631780.060 Why?
Female920223800200.060 Why?
Middle Aged720222132410.050 Why?
Data Collection1201133390.050 Why?
Adolescent42022857290.050 Why?
Follow-Up Studies12021390010.040 Why?
Recurrence2202283370.040 Why?
Male720223497760.040 Why?
Cohort Studies12020405450.040 Why?
Canada1202020640.030 Why?
Fluorodeoxyglucose F181202220160.030 Why?
Remission Induction1201723840.020 Why?
Infant12012351220.020 Why?
Child, Preschool12012409640.020 Why?
Prospective Studies22020532500.020 Why?
Aged, 80 and over22022577440.020 Why?
Survival Analysis12017102510.010 Why?
Gene Expression1201777930.010 Why?
Child12012776370.010 Why?
United States12011698590.010 Why?
Practice Guidelines as Topic1201872700.010 Why?
Quality of Life12020127880.010 Why?
Merryman's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (82)
Explore
_
Co-Authors (40)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.